Elucidating Targetable Genetic Vulnerabilities in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL), the most prevalent form of non-Hodgkin lymphoma is marked by significant heterogeneity in its morphology, genetic irregularities, and clinical behavior. Current prognostic tools, including the International Prognostic Index and cell-of-origin transcriptional cl...
Main Author: | Li, Audrey |
---|---|
Other Authors: | Getz, Gad |
Format: | Thesis |
Published: |
Massachusetts Institute of Technology
2024
|
Online Access: | https://hdl.handle.net/1721.1/156838 |
Similar Items
-
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by: Leonard Jeff Harris, et al.
Published: (2020-11-01) -
Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
by: Eva Gonzalez Barca
Published: (2023-11-01) -
Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
by: Abdulhaq H, et al.
Published: (2023-07-01) -
Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
by: Xiaoshuang Kong, et al.
Published: (2023-04-01) -
Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
by: Xianggui Yuan, et al.
Published: (2022-11-01)